Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is the current standard first-line therapy for patients with metastatic non–small cell lung cancer (NSCLC) ...

Qualitative responses from individuals involved in the resource-limited pediatric oncology centers mentioned above reveal key enablers for the implementation of QI initiatives. 12 First, the alignment ...

With that background, Birken et al 5 aimed to better understand the interplay between oncology and primary care in the follow-up of cancer survivors. The authors mined their electronic health record ...

ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

Guidelines on female and male breast cancer treatment, including use of adjuvant systemic therapies, biomarker test use, and the role of targeted treatments for subtypes like hormone receptor-positive ...

Enzalutamide (ENZA) and abiraterone acetate (AA) are the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the United Kingdom. 1-4 In the real-world ...

PCS involves extensive surgical effort to achieve optimal debulking, defined as no residual tumor or minimal residual disease. This approach has been associated with improved survival rates when ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...